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1. Introduction 
Coronary artery disease (CAD) is one of the most common cardiovascular diseases and has 
a high incidence of morbidity and mortality. CAD is a major public health problem in 
developing and developed countries and its increasing prevalence is a cause of considerable 
concern in the medical community worldwide (He et al., 2005). CAD involves genetic and 
environmental factors and their interaction with each other. Traditional risk factors account 
for at most one-half of the prevalence of CAD (Zdravkovic et al., 2002). Despite attempts to 
establish the molecular and genetic determinants that could account for variations in CAD 
(Zdravkovic et al., 2002), the etiology and complex multigenic basis of atherosclerosis is still 
not completely understood. 
Completion of the sequencing of the human genome was a monumental achievement (Venter 
et al., 2001). Molecular researchers now take for granted the information provided by the 
sequence, however the clinical applications are not immediately obvious. A limitation of the 
Human Genome Project was that it produced only a single “reference” sequence. But in order 
to identify new disease causing mechanisms and cures for disease, we need to go beyond the 
“reference” and characterize the differences between our genomes, and in turn the effect that 
these differences have. The Human HapMap consortium (Frazer et al., 2007) and recent 
genome-wide association studies (GWAS) have set out to capture the interindividual 
differences that are associated with disease processes, including coronary artery disease. 
The association between genetic variations and CAD have been reviewed in several 
previous manuscripts (Lanktree et al., 2008), but in our knowledge so far there has been no 
study in the field of association between novel gene variations and CAD; therefore we 
focused on introducing some novel polymorphisms and their relationships with CAD.  
2. Genetics of coronary artery disease 
2.1 Genetic architecture of CAD 
The success of CAD gene mapping is dependent on its genetic architecture which refers to 
the number of disease genes that exist, their allele frequencies, the risks that they confer, and 
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the interactions between multiple genetic and environmental factors (Wright & Hastie, 2001; 
Reich & Lander, 2001). Although the total genetic contribution to CAD risk can be 
quantified, the determination of the size and number of contributing effects is impossible 
without identifying all CAD susceptibility genes. The multiple risk factors for CAD 
themselves have their own genetic architecture. The heritabilities of some of the risk factors 
for CAD are considerable - total cholesterol (40 to 60%), HDL-cholesterol (45 to 75%), total 
triglycerides (40 to 80%), body mass index (25 to 60%), systolic blood pressure (50 to 70%), 
Lp(a) levels (90%), homocysteine levels (45%), type 2 diabetes (40 to 80%), fibrinogen (20 to 
50%) (Lusis et al., 2004). Also, as CAD is rare before the age of 50 yr, it is unlikely to have an 
effect on reproductive success and hence less likely to have been subject to direct 
evolutionary selection pressure. Variants that confer susceptibility or protection for CAD 
might therefore have evolved neutrally in the past, and so could present at a wide range of 
frequencies. 
This is the basis of the Common Disease/Common Variant (CDCV) hypothesis which holds 
that the genetic variants underlying complex traits occur with a relatively high frequency 
(>1%), have undergone little or no selection in earlier populations and are likely to date back 
to >100,000 years ago (Lander et al., 1996).The other competing model is the Common 
Disease Rare Variant hypothesis, with an inverse relationship between the magnitude of 
genetic effect and allele frequency (Pritchard et al., 2001). This model argues that diseases 
are common because of highly prevalent environmental influences, not because of common 
disease alleles in the population (Wright & Hastie, 2001). A review of candidate gene 
associations and recent genome wide association study results support the importance of 
common alleles in CAD. At odds with this, rare allelic variants of three candidate genes 
(ABCA1, APOA1, LCAT) that influence HDL levels, were jointly found to make a 
substantial contribution to the population distribution of HDL levels (Cohen et al., 2004; 
Frikke-Schmidt et al., 2004). The most likely scenario would be that the allelic spectrum of 
the disease variants is the same as the general spectrum of all disease variants. Under this 
neutral model, although most susceptibility variants are rare with minor allele frequencies 
(MAF) <1 per cent, variants with MAF>1 per cent would account for more than 90 per cent 
of the genetic differences between individuals. It is plausible that these common variants 
might contribute significantly to those common diseases in which susceptibility alleles 
might not be under intense negative selection. 
2.2 Linkage and association studies 
The 2 general types of studies that evaluate the relation between gene polymorphisms and 
disease are linkage analysis and association studies. Linkage analysis investigates the 
cosegregation of polymorphic DNA markers with inheritance of disease in families and has 
been highly successful in the detection of monogenic disorders. However, it is a tedious and 
complicated undertaking in the investigation of polygenic diseases such as CHD. 
Association studies provide an alternative method for dissecting genetically complex 
diseases and typically use the candidate gene approach for their investigation. Based on the 
known pathophysiologic characteristics of a disease, assumptions are made about the genes 
involved in its processes and the hypothesis of the association of these genes with the 
disease is then tested. For a disease such as CHD it makes sense to analyze genes that 
contribute to lipoprotein metabolism, blood pressure, and to diseases such as diabetes 
mellitus, among others. 
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This approach is more directed than is the genome-scan linkage approach, but it is limited 
by our incomplete knowledge of disease mechanisms and thus may miss important 
causative genes. It is worth noting that whereas in linkage analyses “disease” alleles are 
tracked in families, genetic association is a phenomenon of populations and association 
studies compare populations of subjects with and without the disease of interest (Bernhard 
et al., 2000). 
2.3 Linkage studies  
Previous methods for determining genetic linkage of a complex disease relied chiefly upon 
the technique of genome wide scanning of microsatellites (short tandem repeat sequences). 
This required the laborious selection of hundreds of families, particularly sib pairs with MI 
or CAD. Using around 400 microsatellite markers distributed evenly across the genome, the 
goal was to identify a significant linkage peak defined by a logarithm of odds ratio (LOD) 
greater than 3.5 corresponding to a p<10-6 indicating a gene that is in linkage disequilibrium 
(LD) near or even within the microsatellite region. However, identifying disease causing 
genes interspersed within microsatellites has proved to be quite difficult and studies from 
different centers reported varying results - Finland (2q21.2-22 and Xq23-26) (Pajukanta et al. 
2000), Germany (14q32.2) (Broeckel et al., 2002), Iceland (13q12-13) ( Helgadottir et al., 2004), 
US (1p34-36 ,3q13 and 5q31)( Hauser et al., 2004) and UK (2p11, 17p11-17q21) (Farrall et al., 
2006; Samani et al. 2005).  Genomic regions identified in the published linkage studies as 
being correlated with CHF are largely non-overlapping, suggesting genetic and/or 
phenotypic heterogeneity. Two genes, ALOX5AP and MEF2A, have been identified by fine 
mapping studies following the original linkage analysis. The Icelandic locus was replicated 
in population-based studies from Iceland and England, with different haplotypes of the 
ALOX5AP gene (encoding 5-lipoxygenase activating protein) associated with CAD in the 
two countries, and the Icelandic haplotype was also associated with stroke in Iceland and in 
Scotland (Helgadottir et al., 2004; Helgadottir et al., 2005). MEF2A (myocyte enhancer factor 
2A) a transcription factor expressed in coronary artery endothelium was identified by 
linkage analysis in a pedigree in which 13 members had CAD, nine of whom had MI (Wang 
et al., 2003).   
2.4 Genome-wide association studies  
Genome-wide association studies (GWAS) became possible after the publication of the 
International Haplotype Map Project (HapMap) (International HapMap consortium, 2005; 
International HapMap consortium, 2007)  and the development of array-based platforms 
that enable the investigation of up to one million variants in cases and controls of a certain 
disease (or other phenotypic traits). The HapMap was a large collaborative project that 
described the frequencies of genetic variants with a minor allele frequency above 5% in four 
distinct populations: Han Chinese, Japanese, Black African from Nigeria, and Caucasian of 
European ancestryfrom the USA (International HapMap consortium, 2005; International 
HapMap consortium, 2007).   
The first GWAS to be conducted under these modalities  was a large case-control study by 
the Wellcome Trust Case-Control Consortium (WTCCC), in which 14,000 cases affected by 7 
among the most common complex diseases  (CAD, arterial hypertension, rheumatoid 
arthritis, Crohn’s disease, bipolar disorder, and diabetes mellitus types I and II) were 
compared with a set of 3,000 healthy controls. (Wellcome trust case control consortium, 
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2007)  The WTCCC study identified 24 genetic variants associated with at least one of these 
complex diseases and helped to clarify key methodological issues, setting the stage for the 
more than 400 GWAS that were to follow. These GWAS have so far identified more than 250 
loci at which common variants influence the predisposition to diseases that are common 
(i.e., diabetes, autoimmune diseases, and several types of cancer), an achievement that by far 
outweighed that of the previous decade of genetic studies. Results are available in the 
catalogue of published GWAS prepared by the National Cancer Institute (NCI)-National 
Human Genome Research Institute (NHGRI). (Hindorff et al., 2010) The genetic variants 
that can be identified by GWAS are common variants (with at least 5% frequency in the 
population) and have a low effect size; the conferred relative risks, as expressed by odds 
ratio, usually range between 1.1 and 1.5. These results confirm the views that the genetic 
predisposition to common diseases consists of the combined effect of numerous common 
genetic variants, each of a small effect size. However, it should be noted that GWAS identify 
regions of the genome (loci) rather than variants of specific genes. Indeed, the specific 
variant(s) identified by GWAS may simply represent the signal of one or more hidden 
variant(s) (not typed in the arrays used in GWAS). Limitations of GWAS need to be 
mentioned. First, these studies need very large samples of cases and controls. Second, DNA 
and data quality control procedures and statistical analysis need to be carried out by expert 
centers. Third, the overall cost of GWAS, ranging from hundreds of thousands to millions of 
US dollars, is prohibitive for most research groups worldwide. And finally, even after and in 
spite of all quality control procedures, there is still the chance that the results of GWAS 
include false-positive results, so that an independent replication of these results is still 
important even after testing thousands of individuals (Pier et al., 2010)  
3. Candidate genetic factors 
CAD is a complex, multifactorial disorder in which interactions among various genetic and 
environmental influences play an important role. Many genes are likely to be involved in 
some way in the process for CAD (Table 1). Some genetic studies have suggested that 
several gene polymorphisms, including those in the genes for angiotensin-converting 
enzyme (Samadi et al., 2009) and paraoxonase (Fallah et al., 2010) increase the risk for CAD. 
Polymorphisms in the genes for insulin-like growth factor-I and lipoprotein lipase have 
been shown to increase the risk of both CAD and type 2 diabetes (Wang et al., 1996;  
Vaessen et al., 2001). 
There are certain genetic defects that affect activities of some enzymes (cystathionin β-
synthase, methyltransferase and 5, 10-methylenetetrahydrofolate reductase) which may lead 
to homocystinuria. Heterozygosity for deficiency of cystathionin β-synthase is known to be 
linked with arthrosclerosis and thrombotic disease including CAD (Bakir et al., 2001). 
Adiponectin gene locus, chromosome 3q27, is the candidate site for CAD. Adiponectin 
I164T mutation is associated with the metabolic syndrome and coronary artery disease. The 
I164T mutation in the adiponectin gene is reported to be a common genetic background 
associated with the metabolic syndrome and CAD in the Japanese population (Ohashi et al., 
2004) 
The Von Willebrand factor (VWF) may be causally associated with coronary heart disease or 
merely be a marker of endothelial damage. The G allele of the -1793 C/G promoter 
polymorphism in the VWF gene has been associated with higher plasma levels of VWF. Van 
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der Meer et al., (Van der Meer et al., 2004) found a clear association of G allele of the -1793 
C/G polymorphism in the VWF gene with an increased risk of Coronary heart disease. 
 
Location Gene name/Polymorphisms 
17q23 Angiotensin-Converting Enzyme 
 insertion/deletion (intron  16) 
1q42-q43 Angiotensinogen Met235Thr, −6G/A 
3q21-q25 Angiotensin II type1 Receptor 1166A/C 
8q21-q22 Aldosterone Synthase (CYP11B2) −344T/C, Lys173Ar 
14q32.1-q32.2  Bradykinin B2 receptor gene −58T/C 
6p24.1  Endothelin-1 Lys198Asn 
7q36  eNOS Glu298Asp, −786T/C 
17q21.32  Glycoprotein IIIa P1A1/A2 
5q23-31  Glycoprotein Ia 807T/C 
17pter-p12  Glycoprotein Ibǂ Thr145Met 
4q28  ǃfibrinogen −455G/A 
11p11-q12  Prothrombin 20210G/A 
7q21.3-q22  PAI-1 4G/5G (promoter region) 
7q21.3  Paraoxonase1 Arg192Gln, Leu54Met 
8p12-p11.2 Werner Helicase Gene Cys1367Arg 
1p36.3 Methylenetetrahydrofolate reductase 677C/T 
16q24  NADH/NADPH oxidase p22phox242C/T,   640A/G 
5q31.1 CD14  Monocyte Receptor −260C/T 
11q22.3  Stromelysin (MMP3) 5A/6A (promoter region) 
20q11.2-q13.1  Gelatinase B (MMP9) −1562C/T 
19q13.2  ApolipoproteinE E2/E3/E4 
16q21  Cholesteryl Ester Transfer Protein (CETP) Ile405Val 
9q31.1  ABCA1 gene Ile823Met 
3p25 PPAR-gamma Pro12Ala, Pro115Gln 
20q13.11-q13.13 Prostacyclin synthase gene 
Table 1. The common genetic polymorphisms which are thought to be associated with 
myocardial infarction or coronary artery disease. 
4. Novel genetic risk factors 
4.1 MLXIPL 
Triglycerides are produced from either fatty acids obtained directly from the diet or 
synthesized de novo when excess carbohydrates are consumed. Genes that respond to 
glucose contain a specific regulatory site, the carbohydrate response element (ChoRE), in 
their promoter regions. To date, ChoREs have been mapped within the promoter regions of 
the liver-type pyruvate kinase (PK), S14, fatty acid synthase (FAS), acetyl-CoA carboxylase 1 
(ACC), and thioredoxin-interacting protein genes (Towle et al., 2005; Minn et al., 2005). 
ChREBP is a basic helix-loop helix/leucine zipper transcription factor involved in mediating 
glucose-responsive gene activation (Yamashita et al., 2001). Mice with a disruption of the 
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ChREBP gene or hepatocytes treated with siRNA to reduce ChREBP expression cannot 
induce lipogenic gene expression in response to carbohydrate (Iizuka et al., 2004; Dentin et 
al., 2004). In hepatocytes prepared from ChREBP null mice, the induction can be restored by 
the addition of a ChREBP expression vector (Ishii et al., 2004). Thus, ChREBP is essential for 
regulating lipogenic gene expression. However, it has previously reported that ChREBP 
requires an interaction partner, Mlx, to efficiently bind to ChoRE sequences and exert its 
functional activity (Stoeckman et al., 2004). Mlx is a basic helix-loop helix/leucine zipper 
protein that heterodimerizes with several partners, including ChREBP; MondoA, a paralog 
of ChREBP expressed predominantly in skeletal muscle; and the repressors Mad1, Mad4, 
and Mnt (Billin et al., 2000; Billin et al., 1999; Meroni et al., 2000). Expressing a dominant 
negative form of Mlx in hepatocytes completely inhibits the glucose response of a number of 
lipogenic enzyme genes, including PK, S14, ACC, and FAS (Ma et al., 2005). This inhibition 
is rescued by overexpressing ChREBP but not MondoA. Therefore, Mlx is an obligatory 
partner of ChREBP in regulating glucose-responsive lipogenic enzyme genes. 
Recently, SNPs localized within the MLXIPL (MLX intracting protein like; ChREBP, 
carbohydrate response element binding protein) loci have been associated with plasma 
triglycerides (Kooner et al., 2008; Kathiresan et al., 2008). The most significant association 
was described for the rs3812316 SNP (C771G, His241Gln); the CC genotype was associated 
with elevated TGs. The identified SNP is located at evolutionary conserved domain 
responsible for glucose dependent activation of MLXIPL. After activation and binding to the 
MLX, the complex increases the transcription of genes involved, among others, in 
lipogenesis and triglyceride synthesis. Since, elevated plasma triglycerides (TG) are an 
independent risk factor for cardiovascular disease development (Sarwar et al., 2007) and 
MLXIPL loci have been associated with plasma triglycerides, this gene might be a novel 
genetic risk factor for coronary artery disease ( Pan et al., 2009)  
4.2 Resistin 
Resistin is a 10 kDa protein composed of 94 amino acids. It was cloned in 2001 and was 
shown to be a thiazolidinedione (TZD)-regulated cytokine expressed in adipose tissue (Wolf 
et al., 2004). The effect of resistin on insulin action has been extensively investigated in 
laboratory models. It was shown to be involved in hepatic glucose and lipid metabolism and 
appears to play a pivotal role in hepatic insulin resistance (IR) induced by high-fat diet 
(Rajala et al., 2003). Resistin was suggested to affect endothelial function and the migration 
of vascular smooth muscle cells (Cohen & Horel., 2009), which are regarded as key 
pathophysiological mechanisms of atherosclerosis. Further, resistin has been noted to play a 
vital role in increasing the level of very low density lipoprotein (VLDL) and low density 
lipoprotein (LDL) in an obese person (Rizkalla et al., 2009) which is directly atherogenic. 
Resistin induces increases in MCP-1 and sVCAM-1 expression in vascular endothelial cells 
which suggest a possible mechanism that contribute to atherogenesis (Cohen & Horel., 
2009). Recent reports indicate that resistin promotes proliferation of VSMC that occurs 
through both ERK 1/2 and Akt signalling pathways (Calabro et al., 2004). Thus resistin is 
noted to enhance VSMC migration, which is a known component of athermanous plaque 
synthesis (Verma et al., 2003). Resistin promotes foam cell formation via dysregulation of 
scavenger receptors (SR-A) and ATP-binding cassette transporter-A1 (ABCA1) (Lee et al., 
2009) through PPAR gamma. In atherosclerosis, increased level of resistin causes elevation 
of soluble TNF-_ receptor 2, IL-6 and lipoprotein-associated phospholipase A2 (Lp- PLA2) 
(Reilly et al., 2005). 
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With respect to the reported resistin variants, the mostly extensively studied has been the 
promoter variant SNP-420C>G. Functional binding studies have been done with stimulatory 
proteins (Sp)-1 and 3, which bind to the promoter. Their binding has been described to be 
influenced by SNP-420C>G. Sp-1 and 3 were discovered to bind efficiently only to the G-
allele sequence and after binding to increase the activity of the promoter. (Chung et al., 
2005). It seems likely that the more active promoter with the SNP-420C>G G allele is the 
reason for several observations of higher plasma resistin concentration in the G allele 
carriers (Yamauchi et al., 2008). However, in contrast to these studies, it has also been 
reported that the genotypes of SNP-420C>G do not influence the plasma resistin 
concentration in Italian subjects (Norata et al., 2007). Furthermore in a small study of 
polycystic ovary syndrome patients noassociation was detected between SNP-420C>G 
genotype and the serum level of resistin (Escobar-Morreale et al., 2006). 
Recent studies have shown that the resistin levels are significantly correlated with coronary 
artery calcification and are predictive of coronary atherosclerosis in humans (Mohty et al., 
2009). Previous studies described the association among this -420 (C>G) polymorphism, the 
resistin levels and cardiovascular risk factors (Ukkola et al., 2006; Norata et al., 2007) 
However, the association between the serum resistin levels and CHD seemed to be negative, 
and might be controversial for this polymorphism and CAD.  (Norata et al., 2007; Kunnari et 
al. 2005) Differences in the cohorts might explain the different results, depending on which 
ethnic group was tested (Menzaghi et al., 2006; Hivert et al., 2009). Indeed, methodological 
limitations in the commercially available ELISA assays might also result in variations among 
serum levels, which might cause difficulties when comparing results from different 
publications. 
4.3 Renalase 
The kidney, in addition to maintaining fluid and electrolyte homeostasis, performs essential 
endocrine functions (Peart et al., 1977). Patients with end-stage renal disease are at high risk 
for cardiovascular events, even when provided optimal renal replacement therapy (Go et al., 
2004; Anavekar et al., 2004). It has been suggested that failure to replicate the endocrine 
functions of the kidney may contribute to this risk, in association with heightened 
sympathetic tone (Joles & Koomans 2004; Neumann et al., 2004; Wolfe et al., 1999). Renalase, 
a flavin adenine dinucleotide-dependent amine oxidase that is secreted into the blood by the 
kidney, metabolizes circulating catecholamines, and is deficient in chronic kidney disease 
(Xu et al., 2005). Excess catecholamines promote the activity, secretion, and synthesis of 
renalase, providing a novel pathway of negative feedback homeostatic control (Li et al., 
2008). In rodents, parenteral administration of renalase lowers blood pressure, heart rate, 
and cardiac contractility (Xu J, Desir GV 2007). During cardiac ischemia in rats, infusion of 
recombinant renalase reduces myocardial infarct size whereas neonatal nephrectomy leads 
to elevated sympathetic nervous system activity, renalase deficiency, and cardiac 
hypertrophy (Desir 2008; Ghosh et al., 2008). Human renalase is encoded by a 311Kbp gene 
with 10 exons located on chromosome 10q23.33. The major isoform of renalase contains 342 
amino acids comprising a signal peptide (amino acids 1–17), a flavin-adenine dinucleotide 
(FAD) binding domain (amino acids 4–45), and a monoamine oxidase domain (amino acids 
75–342). Evidence exists for at least four alternatively- spliced isoforms of renalase (Desir, 
2009). The most common isoform (renalase1) is encoded by exons 1–4, 6–7, and 9. It is the 
predominant human renalase protein detectable in plasma, kidney, heart, skeletal muscle, 
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and liver. The functional significance of the spliced isoforms is not known. It has weak AA 
similarities to MAO-A and MAO-B and distinct substrate specificity and inhibitor profile, 
which indicates that it represents a new class of FAD-containing monoamine oxidases. 
MAO-A and MAO-B are FAD containing, mitochondrial enzymes that metabolize 
intracellular catecholamines. MAO-A and MAO-B have overlapping substrate specificity; 
catabolize neurotransmitters such as epinephrine, norepinephrine, serotonin, and 
dopamine; and are specifically inhibited by clorgyline and deprenyl, respectively. 
Polyamine oxidase, the other known FAD-containing oxidase, is an intracellular oxidase 
that metabolizes spermine and spermidine and regulates cell growth (Jalkanen & Salmi, 
2001). Unlike MAO-A and MAO-B, which are anchored through the carboxyl terminus to 
the outer mitochondrial membrane (Binda et al., 2002) and confined to intracellular 
compartments, renalase is secreted into the blood, where it is detectable by Western blotting. 
Amine oxidase activity has been measured in human plasma and is believed to be mediated 
by vascular adhesion protein 1 (VAP-1), a copper-containing semicarbazide-sensitive amine 
oxidase that is secreted by smooth muscle cells, adipocytes, and endothelial cells (Salmi & 
Jalkanen, 2001). VAP-1’s substrate specificity and inhibitor profile are very different from 
that of renalase. It metabolizes benzylamine and methylamine and is inhibited by 
semicarbazide and hydroxylamine. Therefore, renalase is the only known amine oxidase 
that is secreted into blood and that metabolizes circulating catecholamines. While the 
hypotensive effect of renalase can be fully accounted for by the observed decrease in 
contractility and heart rate, we cannot categorically exclude the possibility that renalase’s 
effect may be partly receptor mediated. 
A common missense polymorphism in the flavin-adenine dinucleotide-binding domain of 
human renalase (Glu37Asp) has recently been described. This is the only reported common 
coding single-nucleotide polymorphism in the renalase gene, and was recently found to be 
associated with essential hypertension (Zhao et al., 2007). Whether common genetic 
variation at this locus affects cardiac structure, function, and ischemia in humans is not 
known. 
4.4 P-selectin 
P-selectin (GMP-140; granule membrane protein-140) is an adhesion molecule which 
mediates the interaction of activated endothelial cells or platelets with leukocytes. The 
selectin family of adhesion molecules also comprises E- and L-selectin. The genes coding for 
the three selectins are clustered on chromosome 1q21–q24 (Watson et al., 1990). The P-
selectin gene spans >50 kb and contains 17 exons, most of which encode structurally distinct 
domains. P-selectin is stored in a-granules of platelets  and the Weibel–Palade bodies of 
vascular endothelial cells (McEver et al., 1989) it rapidly shifts from the membranes of 
secretory granules to the surface of platelets and endothelial cells upon stimulation by 
oxidized low density lipoprotein (LDL) (Vora et al., 1997), oxygen radicals (Patel et al., 
1991), thrombin (Lorant et al., 1991), cytokines  and various other stimuli (Zimmermann, et 
al., 1990). P-selectin is required for efficient recruitment of neutrophils in acute and chronic 
inflammation (Johnson, R.C., et al. 1995) and recently has been shown to bind T cells on 
vascular endothelial cells. These properties suggest that P-selectin could contribute to 
atherogenesis (Hansson, G.K. , 1989, Libby, P. and Hansson, G.K.,1991). Actually, P-selectin 
expression has been demonstrated to be significantly increased in endothelium overlying 
atherosclerotic plaques, and it is focally expressed in the aorta of hypercholesterolemic 
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rabbits. It has been reported that P-selectin-deficient mice on an atherogenic diet develop 
significantly smaller fatty streaks than non-deficient mice (Johnson, R.C., et al. 1997). In 
humans, plasma P selectin levels have been shown to be increased in diabetic patients, in 
patients with unstable angina, post-angioplasty restenosis and after coronary artery spasm 
(Kaikita, K. , 1995). 
Recent study  that genotyped 5 single nucleotide polymorphisms (SNPs) in P-selectin (SELP) 
(V168M, S290N, N592D, V599L, T715P), 2 SNPs (M62I, S273F) in P-selectin glycoprotein 
ligand-1 (SELPLG), 5 SNPs in CD40LG (−3459A>G, −122A>C, −123A>C, 148T>C, intr4–
13T>C), the H558R SNP in SCN5A, and rs2106261 in ZFHX3. In addition, length 
polymorphisms in SELPLG (36bp-tandem repeat) and CD40LG (CA-repeat) were genotyped 
by PCR methods. None of the gene polymorphisms showed significant differences between 
AMI patients and healthy controls. Among patients with a history of VF (Ventricular 
fibrillation), however, the SELP 168M variant showed a significantly higher prevalence as 
compared with patients without VF. This was the first description of an association of the 
SELP gene variant 168M with primary VF during acute MI. This variant may be a novel 
polymorphism for evaluating the susceptibility for VF in the setting of acute MI. (Elmas, 2010)  
4.5 KDR 
Kinase insert domain-containing receptor/fetal liver kinase-1, also called VEGFR2 (KDR), is 
expressed in a wide variety of cells such as endothelial progenitor cells (EPCs), endothelial 
cells, and primitive and more mature hematopoietic cells. Kinase insert domain-containing 
receptor/ fetal liver kinase-1 is required for the differentiation of EPCs and for the 
movement of EPCs from the posterior primitive streak to the yolk sac, a precondition for the 
subsequent formation of blood vessels (Shalaby et al., 1997). Studies with KDR knockout 
mice have found that KDR plays critical roles in the development and formation of blood 
vessel networks (Fong et al., 1995). Vascular endothelial growth factor binds to 2 tyrosine 
kinase receptors, VEGF receptor-1 (VEGFR1, Flt-1) and KDR, in endothelial cells. The 
mitogenic and chemotactic effects of VEGF are mediated mainly through KDR in 
endothelial cells VEGF receptor signal transduction which is activated through 
autophosphorylation of tyrosine residues in the cytoplasmic kinase domain of KDR. This 
event is followed by activation of downstream signaling pathways such as mitogen-
activated protein kinases, Akt and eNOS, which are essential for migration and proliferation 
of endothelial cells, thereby stimulating angiogenesis (Matsumoto & Claesson-Welsh, 2001). 
After vascular endothelial growth factor (VEGF) binding to KDR, multiple early signaling 
cascades are activated in EPCs and in endothelial cells. An array of biological activities are 
subsequently elicited in vivo and in vitro, including angiogenesis, endothelial survival, 
proliferation, migration, and increased production of nitric oxide and prostaglandin I2 
(Gerber et al., 1994). Dysregulated vessel growth is implicated in the pathogenesis of a wide 
variety of diseases, including proliferative retinopathies, tumors, rheumatoid arthritis, 
atherosclerosis, as well as CHD. (Dimmeler et al., 2001; Rehman et al., 2004; Werner et al., 
2002). The variation of KDR gene may change the biological function of KDR. Bioinformatic 
analysis showed that the single nucleotide polymorphism (SNP) -604T/C (rs2071559) leads 
to structural alteration of the binding site for transcriptional factor E2F (involving in cell 
cycle regulation, interacting with Rb p107 protein) in KDR gene promoter region, which 
may alter KDR expression. Exonic polymorphisms SNP1192G/A (rs2305948, in exon 7) and 
SNP1719A/T (rs1870377, in exon 11) are located in the third and fifth NH2-terminal IG-like 
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domains within the extracellular region, which are important for ligand binding, and result 
in nonsynonymous amino acid changes at residue 297V/I and 472H/Q, respectively. It is 
showed that patients carrying the KDR mutations are more susceptible to CHD. The higher 
CHD risk could be due to downregulation of the VEGF/KDR signaling pathway. However, 
the angiogenesis preceded by VEGF/KDR signaling pathway could be decreased due to low 
KDR activity. The SNP-604T/C decreases mRNA levels of KDR and both SNP1192G/A and 
SNP1719T/A resulted in slight but significant decrease in the VEGF binding efficiency to 
KDR. One can speculate that the decrease in KDR function is correlated with vascular 
dysfunction, including endothelial cell damage, impaired endothelial cell survival, 
decreased antiapoptotic effects of VEGF, and abnormal vascular repair. All of these can 
promote the progression of atherosclerotic disease. A previous study has suggested that -
907T/C, -11903G/A, and -18487A/T (now called SNP-604, SNP1192, and SNP1719, 
respectively) have no significant association with the development of coronary artery lesion 
in Japanese subjects with Kawasaki disease (Kariyazono et al., 2004). The differences 
between the studies could be due to the different pathologic mechanism between the 
coronary artery lesion with Kawasaki disease and CHD, different genetic background of the 
populations as well as the sample size in different studies. (Schmidt-Lucke et al., 2005). The 
genotype frequencies of the 3 SNPs from the HapMap data were similar to others. The 
rs2071559 can capture rs7667298 (exon_1, untranslated). No linkage disequilibrium was 
found in rs2305948 with other SNPs in HapMap CHB data. The rs1870377 (exon_11) can 
capture rs10016064 (intron_13), rs17085265 (intron_21), rs3816584 (intron_16), rs6838752 
(intron_17), rs1870379 (intron_15), rs2219471 (intron_20), rs1870378 (intron_15), rs13136007 
(intron_13), and rs17085262 (intron_21). The results showed that 2 blocks were captured by 
SNP-604 (rs2071559) and SNP1719 (rs1870377), respectively, and SNP1192 (rs2305948) were 
associated with CHD. 
5. Other novel polymorphisms 
Asymmetrical dimethylarginine (ADMA), an endogenous arginine analogue, inhibits nitric 
oxide synthases and plays an important role in endothelial dysfunction. The results suggest 
that the DDAH1 (dimethylarginine dimethylaminohydrolase 1) loss-of-function 
polymorphism is associated with both increased risk of thrombosis stroke and CAD (Ding et 
al., 2010). Growing evidence has shown that inflammation plays crucial roles in the 
development of coronary artery disease. Interleukin-16 (IL-16), a multifunctional cytokine, is 
involved in a series of inflammatory disorders. One finding indicates that IL-16 may be used 
as a genetic marker for CAD susceptibility (Wu et al., 2010). Two single-nucleotide 
polymorphisms (SNPs), rs1746048 and rs501120, from genome wide association studies of 
coronary artery disease map to chromosome 10q11 ~80 kb downstream of chemokine 
CXCL12. Coronary artery disease risk alleles downstream of CXCL12 are associated with 
plasma protein levels of CXCL12 and appear to be related to CXCL12 transcript levels in two 
human cell lines. This implicates CXCL12 as potentially causal and supports CXCL12 as a 
potential therapeutic target for CAD ( Nehal et al., 2011). 
6. Conclusion 
Studying only one SNP may be an overly simplistic method in investigating a complex 
disease such as CAD. Complex traits such as CAD, more large databases of high-quality 
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genetic and clinical data need to be established and since genes and environmental factors 
are both involved in this disease; environmental causes and gene-environment interactions 
must be carefully assessed. These results will provide clues to the involvement and 
investigation of novel candidate genes in association studies.  Large replication studies with 
different ethic samples are needed to investigate whether there are ethnic differences in the 
influence of novel polymorphisms on coronary artery disease. This issue should be 
investigated with different ethnic samples in the future. Therefore studies with large sample 
size of coronary artery disease and different ethnicity will be welcome to help elucidate the 
interconnection between novel genetics and pathogenesis of coronary artery disease.  
7. Abbreviations 
ABCA1: ATP-binding cassette transporter 1 
ACC: acetyl-CoA carboxylase 
ALOX5AP: Arachidonate 5-lipoxygenase-activating protein. 
APOA1: Apolipoprotein A1 
CAD: Coronary artery disease 
LCAT: Lecithin-cholesterol acyltransferase 
CHD: Coronary heart disease 
ChoRE: Carbohydrate response element 
ChREBP: Carbohydrate response element binding protein 
ELISA: Enzyme-linked immunosorbent assay 
EPCs: Endothelial progenitor cells  
ERK 1/2 : Extracellular signal-regulated kinases1/2 
FAD: Flavin-adenine dinucleotide  
FAS: Fatty acid synthase 
GWAS: Genome-wide association Studies 
HDL: High-density lipoprotein 
KDR: Kinase insert domain-containing receptor  
Lp- PLA2: Lipoprotein-associated phospholipase A2  
Mad1: Mitotic arrest deficient-like 1 
Mad4: Mitotic arrest deficient-like 4 
MAO-A: L-Monoamine oxidases A  
MAO-B : L-Monoamine oxidases B 
MEF2A: Myocyte enhancer factor 2A 
MlX: Max-like x protein 
PPAR: Peroxisome proliferator-activated receptors  
PK : Pyruvate kinase  
siRNA: Small interfering RNA 
SNPs: Single nucleotide polymorphisms 
Sp1: stimulatory proteins 1  
SR-A: Scavenger receptors A  
TNF: Tumor necrosis factors 
VAP-1: vascular adhesion protein 1  
VCAM-1:  Vascular cell adhesion protein 1 
VF: Ventricular fibrillation  
VLDL: Very low density lipoprotein  
VWF: Von Willebrand factor 
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